Publications

• Kagiava A and Kleopa KA; “Facing the challenge of effective dosing, safety, and timing of intrathecal gene therapy for neurological disorders”. eBiomedicine. 2026 https://pmc.ncbi.nlm.nih.gov/articles/PMC12685547/
• Christou M., Sargiannidou I., Papacharalambous R., Richter J., Tryfonos C., Christodoulou C., Kagiava A., Kleopa KA.; “A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X” Neurotherapeutics 2025 https://pubmed.ncbi.nlm.nih.gov/40055046/
• Kagiava A., Karaiskos C., Lapathitis G., Heslegrave A., Sargiannidou I., Zetterberg H., Bosch A., Kleopa K.A.; “Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy”. Mol. Ther Methods Clin Dev. 2023 https://pubmed.ncbi.nlm.nih.gov/37645436/
• Kagiava A., Richter J., Tryfonos C., Leal-Julià M., Sargiannidou I., Christodoulou C., Bosch A. and Kleopa KA; “Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery”. Sci Rep. 2021 https://pubmed.ncbi.nlm.nih.gov/34857831/
• Kagiava A., Karaiskos C., Richter J., Tryfonos C., Jennings M., Heslegrave M., Sargiannidou I., Stavrou M., Zetterberg H., Reilly M., Christodoulou C., Horvath R., Kleopa KA; “AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy”. Gene Therapy. 2021 https://pmc.ncbi.nlm.nih.gov/articles/PMC8599011/
• Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA. “Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X”; Hum Mol Genet. 2019 https://pubmed.ncbi.nlm.nih.gov/31411673/
• Kagiava A. and Kleopa K.A. “Intrathecal Delivery of Viral Vectors for Gene Therapy”; Methods Mol Biol. 2018 https://pubmed.ncbi.nlm.nih.gov/30006718/
• Kagiava A., Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., Christodoulou C., Kleopa K.A. “Intrathecal gene therapy in mouse models expressing CMT1X mutations”; Hum Mol Genet. 2018 https://pubmed.ncbi.nlm.nih.gov/29462293/
• Kagiava A., Sargiannidou I., Theophilidis G., Karaiskos C., Richter J., Bashiardes S., Schiza N., Nearchou M., Christodoulou C, Scherer SS, Kleopa KA. “Intrathecal gene delivery for the treatment of inherited peripheral neuropathies”; PNAS, 2016 https://pubmed.ncbi.nlm.nih.gov/27035961/

Awards 

2023: Meritorious Abstract Travel Award from the American Society of Gene&Cell Therapy (ASGCT) at the ASGCT 26th Annual Meeting “AAVrh10 Schwann cell targeted gene replacement therapy for CMT1X demyelinating neuropathy” (16-20 May 2023) 
2016: Young Researcher Award 2016 (Life Sciences) of the Cyprus Research Promotion Foundation 
2016:  Awarded with the Panos Ioannou Junior Scientist Award 
2014: Travel grant from FENS/IBRO for poster presentation at the 9th Forum of European      Neuroscience Societies, Milan, Italy, “Gene delivery targeted to myelinating cells to treat inherited neuropathies and leukodystrophy” (5-9 July 2014) 
2013:  Travel grant from PNS Society for poster presentation in the PNS Biennial Meeting, Saint-Malo, Brittany, France, “Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study” (29 June -3 July 2013) 
2011: Second award for Oral presentation in 17th Hellenic Conference of Clinical Oncology, Athens, Greece, “Effects of oxaliplatin on the action potential of nerve axons of peripheral nervous system” (April 14-16 2011) 
2010: Travel grant from FENS/IBRO for poster presentation in 7th Forum of European Neuroscience Societies, Amsterdam, Netherlands, “Assessment of the neurotoxic effects of palytoxin and palytoxin-like compounds produced by Ostreopsis species, affecting the Na+/K+-ATPase pump, using the isolated mouse sciatic nerve” (July 3-7 2010) 
2006: Travel grant for attending the Onassis Foundations Science Lectures Series «Brain Plasticity: From Molecules to Behavior» (17-21 July 2006, Heraklion-Crete). Invited speaker: Eric Kandel Nobel Prize winner 
2007: Travel grant for attending the Onassis Foundations Science Lectures Series «Channels and Channelopathies» (2-6 July 2007, Heraklion-Crete). Invited speaker: Peter Agre Nobel Prize winner 

Grants

SMALL SCALE INFRASTRUCTURES/1222/0095 12/01/2023-05/30/2026 “Experimental Electrophysiology Unit” Role: PI (737000€)

MDA952763, Charcot-Marie-Tooth Association and Muscular Dystrophy Association 10/01/2023-06/30/2026 “Nanoparticle-based gene delivery to Schwann cells for treating CMT disease” Role: PI ($299995)

COST action CA23106, “An Evolutionary View to Understanding Affective States across Species (AFFECT-EVO)”, 10/10/24-9/10/28 Role: Member of the Managerial Committee

MDA963041, Muscular Dystrophy Association 09/01/2022-11/30/2023 “Ultrasound-induced access of therapeutics to peripheral nerves” Role: PI ($50000)

EXCELLENCE/0918/131, The Cyprus Research and Innovation Foundation 10/01/2019-03/31/2022 “Development of translatable cell targeted gene delivery to peripheral nerves” Role: PI (250000€)

CULTURE/ΒΡ-ΝΕ/0416/07, The Cyprus Research and Innovation Foundation, 05/01/2017-07/31/2019 “Evaluation of gene therapy in a CMT1X model with advanced peripheral neuropathy” Role: PI (35000€)